Equities analysts expect Turning Point Therapeutics (NASDAQ:TPTX) to announce ($0.57) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Turning Point Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.63). The business is scheduled to announce its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Turning Point Therapeutics will report full-year earnings of ($2.88) per share for the current financial year. For the next fiscal year, analysts expect that the company will report earnings of ($3.11) per share, with EPS estimates ranging from ($3.53) to ($2.68). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Turning Point Therapeutics.

Turning Point Therapeutics (NASDAQ:TPTX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.05).

TPTX has been the subject of several analyst reports. Svb Leerink initiated coverage on Turning Point Therapeutics in a report on Monday, May 13th. They issued an “outperform” rating and a $42.00 price target for the company. Canaccord Genuity initiated coverage on Turning Point Therapeutics in a report on Monday, May 13th. They issued a “buy” rating and a $48.00 price target for the company. Wells Fargo & Co initiated coverage on Turning Point Therapeutics in a report on Monday, May 13th. They issued an “outperform” rating and a $53.00 price target for the company. Goldman Sachs Group initiated coverage on Turning Point Therapeutics in a report on Monday, May 13th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Royal Bank of Canada initiated coverage on Turning Point Therapeutics in a report on Monday, May 13th. They issued an “outperform” rating and a $48.00 price target for the company. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Turning Point Therapeutics has an average rating of “Buy” and an average target price of $48.71.

Several hedge funds and other institutional investors have recently made changes to their positions in TPTX. Cormorant Asset Management LP purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $127,080,000. Orbimed Advisors LLC purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $104,499,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $36,225,000. BlackRock Inc. purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $23,520,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Turning Point Therapeutics during the 2nd quarter valued at $17,712,000. 0.03% of the stock is owned by institutional investors.

TPTX traded up $0.01 during trading on Friday, hitting $42.42. The company’s stock had a trading volume of 147,700 shares, compared to its average volume of 93,603. The business has a 50 day simple moving average of $41.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 32.35 and a current ratio of 32.35. Turning Point Therapeutics has a twelve month low of $24.21 and a twelve month high of $47.72.

Turning Point Therapeutics Company Profile

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Further Reading: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Turning Point Therapeutics (TPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.